Clinical trials
Graves Ophthalmopathy trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 8 |
| 2025 | 11 |
| 2026 | 11 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 20 |
| Unknown status | 13 |
| Completed | 11 |
| Active, not recruiting | 3 |
| Not yet recruiting | 3 |
| Terminated | 2 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 13 |
| Innovent Biologics (Suzhou) Co. Ltd. | 6 |
| Shanghai Changzheng Hospital | 6 |
| Minghui Pharmaceutical (Hangzhou) Ltd | 3 |
| Amgen | 2 |
| Beijing Kanghong Biological Medicine Co., Ltd. | 2 |
| Peking University Third Hospital | 2 |
| argenx | 2 |
| Candid Therapeutics | 1 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Graves Ophthalmopathy | 54 |
| Graves Disease | 3 |
| Autoimmune Diseases | 2 |
| Endocrine System Diseases | 2 |
| Eye Diseases, Hereditary | 2 |
| Hyperthyroidism | 2 |
| Immune System Diseases | 2 |
| Thyroid Diseases | 2 |
| Eye Diseases | 1 |
| Optic Nerve Diseases | 1 |
Trials
Showing 26 to 50 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.